2015-E03B/ovarian cancer chemoprevention (SHETA2) period of performance 09/24/2015 - 09/23/2017
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $509,357
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $509,357.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $509,357 |
About this award
This federal contract award, valued at $509,357.00, was issued by the National Cancer Institute (NCI) to SRI International, a non-profit research and development organization. The contract, titled "OVARIAN CANCER CHEMOPREVENTION (SHETA2)," is part of the NCI's Preclinical Prevention Cancer Program and is focused on preclinical efficacy and intermediate endpoint biomarkers related to ovarian cancer. The period of performance runs from September 24, 2015 to September 23, 2017, with a final completion date of January 25, 2018. This contract is a Delivery Order issued under the NCI's larger "PREVENT Cancer Program (PREVENT)" indefinite delivery vehicle (IDV), which allows the agency to efficiently procure biomedical research services from SRI International across a range of areas. The contract does not have a small business set-aside designation.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on September 24, 2015.
How much is contract HHSN26100002 worth?
The government has obligated $509,357 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201500041I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award